Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy

Published Apr 08 2021 at 12:31 PM GMT
Key
Points
  • APX3330 has the Potential to be a Novel Oral Treatment Option with Dual Mechanism of"Anti-VEGF and Anti-Inflammatory for Diabetic Retinopathy Top Line Data from ZETA-1 Expected by Early 2022 FARMINGTON HILLS, Mich., April 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc.
  • (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that it has screened the first patient in ZETA-1, a Phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR).
  • Effects on diabetic macular edema will be explored as a secondary outcome.
  • A number of retinal centers across the US are active and recruiting eligible diabetic retinopathy patients.
  • Diabetes is the leading cause of blindness among adults aged 20 " 74.




Stats

  • Published Apr 8, 2021 12:31 PM GMT